Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

Bibliographic Details
Main Author: Simões,Belinda Pinto
Publication Date: 2011
Other Authors: Braga Junior,José Wilson Ramos, Rego,Maria Aparecida do Carmo, Souza,Cármino Antônio de
Format: Article
Language: eng
Source: Revista brasileira de hematologia e hemoterapia (Online)
Download full: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100017
Summary: Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results
id ABHHTC-1_4296e36b09eadbe7f0a75a50d844810c
oai_identifier_str oai:scielo:S1516-84842011000100017
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intoleranceLeukemia, myelogenous, chronic, BCR-ABL positive/drug therapyDrug resistanceDrug monitoring, neoplasmReceptor Protein-Tyrosine KinasesPyrimidines/therapeutic useAntineoplastic agents/administration & dosageMonitoringPrognosisImatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better resultsAssociação Brasileira de Hematologia e Hemoterapia e Terapia Celular2011-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100017Revista Brasileira de Hematologia e Hemoterapia v.33 n.1 2011reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.5581/1516-8484.20110017info:eu-repo/semantics/openAccessSimões,Belinda PintoBraga Junior,José Wilson RamosRego,Maria Aparecida do CarmoSouza,Cármino Antônio deeng2011-05-05T00:00:00Zoai:scielo:S1516-84842011000100017Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2011-05-05T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
title Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
spellingShingle Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
Simões,Belinda Pinto
Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy
Drug resistance
Drug monitoring, neoplasm
Receptor Protein-Tyrosine Kinases
Pyrimidines/therapeutic use
Antineoplastic agents/administration & dosage
Monitoring
Prognosis
title_short Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
title_full Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
title_fullStr Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
title_full_unstemmed Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
title_sort Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
author Simões,Belinda Pinto
author_facet Simões,Belinda Pinto
Braga Junior,José Wilson Ramos
Rego,Maria Aparecida do Carmo
Souza,Cármino Antônio de
author_role author
author2 Braga Junior,José Wilson Ramos
Rego,Maria Aparecida do Carmo
Souza,Cármino Antônio de
author2_role author
author
author
dc.contributor.author.fl_str_mv Simões,Belinda Pinto
Braga Junior,José Wilson Ramos
Rego,Maria Aparecida do Carmo
Souza,Cármino Antônio de
dc.subject.por.fl_str_mv Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy
Drug resistance
Drug monitoring, neoplasm
Receptor Protein-Tyrosine Kinases
Pyrimidines/therapeutic use
Antineoplastic agents/administration & dosage
Monitoring
Prognosis
topic Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy
Drug resistance
Drug monitoring, neoplasm
Receptor Protein-Tyrosine Kinases
Pyrimidines/therapeutic use
Antineoplastic agents/administration & dosage
Monitoring
Prognosis
description Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results
publishDate 2011
dc.date.none.fl_str_mv 2011-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100017
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5581/1516-8484.20110017
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.33 n.1 2011
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213111171121152

Similar Items